Nanoform Finland Feed

	Est. tid*
2026-02-26	07:10	Bokslutskommuniké 2025
2025-11-20	07:10	Kvartalsrapport 2025-Q3
2025-08-21	07:10	Kvartalsrapport 2025-Q2
2025-05-20	-	Kvartalsrapport 2025-Q1
2025-04-16	-	X-dag ordinarie utdelning NANOFH 0.00 EUR
2025-04-15	-	Årsstämma
2025-02-27	-	Bokslutskommuniké 2024
2024-11-18	-	Kvartalsrapport 2024-Q3
2024-08-29	-	Kvartalsrapport 2024-Q2
2024-05-30	-	Kvartalsrapport 2024-Q1
2024-04-17	-	X-dag ordinarie utdelning NANOFH 0.00 EUR
2024-04-16	-	Årsstämma
2024-02-29	-	Bokslutskommuniké 2023
2023-11-22	-	Kvartalsrapport 2023-Q3
2023-08-24	-	Kvartalsrapport 2023-Q2
2023-05-25	-	Kvartalsrapport 2023-Q1
2023-04-13	-	X-dag ordinarie utdelning NANOFH 0.00 EUR
2023-04-12	-	Årsstämma
2023-02-28	-	Bokslutskommuniké 2022
2022-11-29	-	Kvartalsrapport 2022-Q3
2022-08-25	-	Kvartalsrapport 2022-Q2
2022-05-24	-	Kvartalsrapport 2022-Q1
2022-04-13	-	X-dag ordinarie utdelning NANOFH 0.00 EUR
2022-04-12	-	Årsstämma
2022-02-22	-	Bokslutskommuniké 2021
2021-11-25	-	Kvartalsrapport 2021-Q3
2021-11-17	-	Extra Bolagsstämma 2021
2021-08-26	-	Kvartalsrapport 2021-Q2
2021-05-27	-	Kvartalsrapport 2021-Q1
2021-04-07	-	X-dag ordinarie utdelning NANOFH 0.00 EUR
2021-04-06	-	Årsstämma
2021-02-26	-	Bokslutskommuniké 2020
2020-11-27	-	Kvartalsrapport 2020-Q3
2020-09-01	-	Extra Bolagsstämma 2020
2020-08-28	-	Kvartalsrapport 2020-Q2

Land	Finland
Lista	First North Finland
Sektor	Hälsovård
Industri	Medicinteknik

2025-06-19 08:00:00 NANOFORM SECURES €5 MILLION R&D LOAN FROM BUSINESS FINLAND TO ADVANCE CLINICAL DEVELOPMENT OF NANOAPALUTAMIDE 1,16 EUR | +2,65%

2025-06-17 19:32:00 Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 1,13 EUR | +10,78%

2025-06-17 19:32:00 Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma 1,13 EUR | +10,78%

2025-06-17 19:32:00 Nanoform Finland Plc – Manager’s Transactions – Miguel Calado 1,13 EUR | +10,78%

2025-06-17 19:30:00 Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2025 on remuneration of the Board of Directors 1,13 EUR | +10,78%

2025-06-12 07:10:00 Nanoform starts Pivotal Human Bioequivalence Studies of Nanoenzalutamide 0,75 EUR | -4,21%

2025-06-03 07:10:00 DEVELOPMENT OF NANOFORMED TRASTUZUMAB FOR SUBCUTANEOUS INJECTION TO BE PRESENTED AT DDF SUMMIT IN BERLIN 0,89 EUR | -1,11%

2025-05-30 08:45:00 Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 0,90 EUR | -0,22%

2025-05-30 08:45:00 Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen 0,90 EUR | -0,22%

2025-05-28 16:00:00 POSITIVE NANOFORM BIOLOGICS RESPIRATORY DATA TO BE PRESENTED AT DRUG DELIVERY AND FORMULATION SUMMIT 0,90 EUR | -5,46%

2025-05-20 07:10:00 Nanoform Q1 2025 report: Deal mosaic emerge and commercial value clearly seen in our CESS® technology 0,94 EUR | -2,40%

2025-05-20 06:45:00 INSIDE INFORMATION MADE PUBLIC: NANOFORM PARTNERS WITH TWO SPECIALIST HEALTHCARE INVESTORS TO DEVELOP AND COMMERCIALISE NANOENCORAFENIB 0,94 EUR | -2,40%

2025-05-06 10:00:00 Invitation to Nanoform’s Q1 2025 Report Presentation 0,98 EUR | -1,50%

2025-04-15 13:10:00 Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc 1,10 EUR | -1,79%

2025-04-15 13:00:00 Resolutions of Nanoform Finland Plc's Annual General Meeting on April 15, 2025 1,10 EUR | -1,79%

2025-03-17 16:15:00 Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen 1,18 EUR | +0,34%

2025-03-17 16:15:00 Notice to the Annual General Meeting of NANOFORM FINLAND Plc 1,18 EUR | +0,34%

2025-02-27 07:10:00 Nanoform 2024 report: Deal discussions around product kernels intensify 1,16 EUR | -5,68%

2025-02-13 10:00:00 Invitation to Nanoform’s Q4 and FY 2024 Report Presentation 1,15 EUR | -2,21%

2024-12-18 16:01:00 Nanoform Finland Plc – Manager’s Transactions – Edward Hæggström 1,29 EUR | +2,70%

2024-12-18 16:01:00 Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 1,29 EUR | +2,70%

2024-12-18 16:01:00 Nanoform Finland Plc – Managers’ transactions – Antonio Da Silva 1,29 EUR | +2,70%

2024-12-18 16:01:00 Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen 1,29 EUR | +2,70%

2024-12-18 16:00:00 The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees 1,29 EUR | +2,70%

2024-11-19 19:45:00 Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen 1,40 EUR | +17,88%

2024-11-19 19:45:00 Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 1,40 EUR | +17,88%

2024-11-18 07:10:00 Nanoform Q3 2024 report: Record number of new projects signed 1,11 EUR | -1,77%

2024-11-04 10:00:00 Invitation to Nanoform’s Q3 2024 Report Presentation 1,22 EUR | -6,14%

2024-10-25 15:15:00 Disclosure as attachment of the Nanoform 2022 Report of the Board of Directors and Financial Statements which were previously linked to a Company Release 1,51 EUR | 0,00%

2024-10-22 18:20:00 Share subscriptions based on Nanoform Finland Plc’s stock options 2/2019 1,51 EUR | -2,58%

2024-09-05 07:10:00 Nanoform and Celanese Expand Collaboration into Long-Acting Biologics Delivery Through Small Implants 1,85 EUR | 0,00%

2024-08-29 07:10:00 Nanoform Q2 report: All business targets for 2024 on track 1,85 EUR | +3,13%

2024-08-16 10:00:00 Invitation to Nanoform’s Q2 2024 Report Presentation 1,72 EUR | -1,04%

2024-08-15 07:10:00 NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT 1,74 EUR | +1,28%

2024-06-14 16:01:00 Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma 1,85 EUR | -2,52%

2024-06-14 16:01:00 Nanoform Finland Plc – Manager’s Transactions – Miguel Calado 1,85 EUR | -2,52%

2024-06-14 16:01:00 Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 1,85 EUR | -2,52%

2024-06-14 16:01:00 Nanoform Finland Plc – Manager’s Transactions – Mads Laustsen 1,85 EUR | -2,52%

2024-06-14 16:00:00 Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2024 on remuneration of the Board of Directors 1,85 EUR | -2,52%

2024-05-30 07:10:00 Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned 1,96 EUR | -7,30%

2024-05-29 11:30:00 Disclosure of Major Holdings under Law 163/2024 2,11 EUR | -3,65%

2024-05-16 10:00:00 Invitation to Nanoform’s Q1 2024 Report Presentation 2,00 EUR | +5,08%

2024-05-07 08:10:00 Nanoformed High-Concentration Biologics Formulation for Subcutaneous Delivery Results to be Presented by Takeda at DDF Summit 2,04 EUR | -3,31%

2024-04-26 10:00:00 Disclosure of Major Holdings under Law 163/2024 2,15 EUR | +6,16%

2024-04-25 16:00:00 New shares of Nanoform registered with the trade register 2,03 EUR | -21,77%

2024-04-24 21:50:00 Nanoform successfully completes new share issue raising EUR 15.4 million to invest in commercialization of nanoparticle enabled formulations for next generation medicines 2,03 EUR | -21,77%

2024-04-24 17:31:00 Nanoform announces its intention to carry out a new share issue of approximately 7 million new shares to invest in commercialization of nanoparticle enabled formulations for next generation medicines 2,03 EUR | -21,77%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Nanoform Finland

Prenumeration

Kalender

Beskrivning

Nanoform Finland

Prenumeration

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden